| Literature DB >> 26250868 |
Hui Wang1,2, Souhayla El Maadidi2, Janett Fischer2,3, Elena Grabski4, Sabine Dickhöfer2, Sascha Klimosch2, Sinead M Flannery5, Angela Filomena6, Olaf-Oliver Wolz2, Nicole Schneiderhan-Marra6, Markus W Löffler2,7, Manfred Wiese3, Tica Pichulik2, Beat Müllhaupt8, David Semela9, Jean-François Dufour10, Pierre-Yves Bochud11, Andrew G Bowie5, Ulrich Kalinke4, Thomas Berg3, Alexander N R Weber1,2.
Abstract
UNLABELLED: Patients carrying very rare loss-of-function mutations in interleukin-1 receptor-associated kinase 4 (IRAK4), a critical signaling mediator in Toll-like receptor signaling, are severely immunodeficient, highlighting the paramount role of IRAK kinases in innate immunity. We discovered a comparatively frequent coding variant of the enigmatic human IRAK2, L392V (rs3844283), which is found homozygously in ∼15% of Caucasians, to be associated with a reduced ability to induce interferon-alpha in primary human plasmacytoid dendritic cells in response to hepatitis C virus (HCV). Cytokine production in response to purified Toll-like receptor agonists was also impaired. Additionally, rs3844283 was epidemiologically associated with a chronic course of HCV infection in two independent HCV cohorts and emerged as an independent predictor of chronic HCV disease. Mechanistically, IRAK2 L392V showed intact binding to, but impaired ubiquitination of, tumor necrosis factor receptor-associated factor 6, a vital step in signal transduction.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26250868 DOI: 10.1002/hep.28105
Source DB: PubMed Journal: Hepatology ISSN: 0270-9139 Impact factor: 17.425